Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

Clinical Study of Edwards Cardioband FIT Valve Repair System

NCT03382457 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2018-07-01
Last updated
2026-05-08

Condition(s) studied

Tricuspid Regurgitation

Investigational drug(s) / intervention(s)

Transcatheter Tricuspid Valve Repair

Transcatheter Tricuspid Valve Repair: Repair of the tricuspid valve through a transcatheter approach

Study summary

Clinical Study of the Edwards Cardioband FIT Repair System

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: * Tricuspid regurgitation (moderate or greater) * Despite medical therapy, per the local Heart Team, patient has signs of TR, symptoms from TR, or prior heart failure hospitalization from TR. * The local site Heart Team determines that the patient is appropriate for transcatheter tricuspid reconstruction * Patient is willing and able to comply with all specified study evaluations and provides written informed consent Key Exclusion Criteria: Patients with conditions or anatomical considerations that preclude safe and successful procedure-related or study device access, deployment, or function, including but not limited to: * Patients in whom transesophageal echocardiography is contraindicated or cannot be completed. * Patients in whom tricuspid valve anatomy is not evaluable by TTE or TEE * Untreatable hypersensitivity or contraindication to any of the following: all antiplatelets, all anticoagulants, nitinol alloys (nickel and titanium), polyester, or contrast media. * Previous tricuspid valve repair or replacement with device in place * Presence of trans-tricuspid pacemaker or defibrillator leads where: (a)TR is a result of impingement on the tricuspid valve leaflet as evaluated by echocardiography; or (b) implanted in the RV within the last 90 days Primary tricuspid valve disease Any physical impairment which limits the patient's capacity to complete functional testing due to other medical conditions independent of their TR (e.g., orthopedic condition) Currently participating in another investigational biologic, drug, or device study Any of the following cardiovascular procedures: * Percutaneous coronary, intracardiac, or endovascular intervention within the last 30 days * Carotid surgery within the last 30 days * Direct current cardioversion within the last 30 days * Leadless RV pacemaker implant within the last 30 days * Cardiac surgery within the last 90 days Any of the following underlying medical conditions: * Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation * Active endocarditis or infection requiring antibiotic therapy (oral or intravenous) * Hemodynamically significant pericardial effusion * Significant intra-cardiac mass, thrombus, or vegetation * Untreated clinically significant coronary artery disease (CAD) requiring revascularization, evidence of acute coronary syndrome, or recent myocardial infarction (MI) * Known history of untreated severe symptomatic carotid stenosis (\>50% by ultrasound) or asymptomatic carotid stenosis (\>70% by ultrasound) * Hypotension (systolic pressure \<90 mmHg) or requirement for inotropic support or hemodynamic support within the last 30 days * Known bleeding or clotting disorders or patient refuses blood transfusion * Active GI bleeding * Recent stroke * Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months or any planned percutaneous cardiac procedure within the next 90 days * Deep vein thrombosis (DVT) or pulmonary embolism (PE) in the last 6 months Pregnant, breastfeeding, or planning pregnancy within the next 12 months Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator

Primary outcome measure(s)

  • Primary Safety Endpoint -Composite Major Adverse Event (MAE) Rate — 30 days
    Number and percentage of patients who experienced at least one major adverse event (MAE).
  • Primary Performance Endpoint - Intraprocedural Success — Intraprocedural
    Number of patients who had Intraprocedural Success, definition modified from TVARC criteria. Per patient analysis.
  • Primary Performance Endpoint - Clinical Success — 30 days and 1 year
    Number of patients who had Clinical Success at 30 days and 1 year, definition modified from TVARC criteria. Per patient analysis.

Trial sites (9)

FacilityCityRegionStatus
Northwestern University Chicago Illinois
Mayo Clinic Rochester Minnesota
Morristown Medical Center Morristown New Jersey
Columbia University Medical Center /New York Presbyterian Hospital New York New York
Oregon Health & Science University Portland Oregon
Lankenau Medical Center Wynnewood Pennsylvania
Heart Hospital Baylor Plano Plano Texas
Intermountain Medical Center Murray Utah
University of Virginia Health System Charlottesville Virginia
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03382457 on ClinicalTrials.gov ↗ ← All trials in the USA